What are the guidelines for using dydrogesterone (progestogen) and bed rest in the context of abortion?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Guidelines for Dydrogesterone and Bed Rest in Abortion Management

Dydrogesterone for Threatened Abortion

Dydrogesterone 40 mg stat dose followed by 10 mg twice daily for one week significantly reduces miscarriage rates in threatened abortion, with a 95.9% pregnancy continuation rate compared to 86.3% with conservative management alone. 1

Evidence for Dydrogesterone Use

  • First trimester threatened abortion: Dydrogesterone treatment reduces miscarriage rates by 47% (odds ratio 0.47, CI 0.31-0.7), with an absolute reduction of 11% in miscarriage incidence (13% vs 24% in controls). 2

  • Dosing regimen: The standard protocol involves 40 mg stat dose followed by 10 mg twice daily for one week when vaginal bleeding occurs before 13 weeks gestation. 1

  • Mechanism of action: Dydrogesterone increases progesterone-induced blocking factor (PIBF) concentrations, which has anti-abortive effects by modulating maternal immune response. 3

Recurrent Spontaneous Abortion Prevention

  • For women with history of recurrent miscarriage: Dydrogesterone 10 mg twice daily started immediately after pregnancy confirmation and continued until 12 weeks gestation reduces abortion rates from 29% (controls) to 13.4%. 4

  • Treatment initiation: Begin as soon as pregnancy is confirmed in women with history of recurrent unexplained spontaneous abortion (mean 3.5 prior abortions). 4

Safety Profile

  • Dydrogesterone demonstrates minimal adverse effects and side effects across multiple studies involving 1,380 patients. 2

  • No differences in pregnancy complications or congenital abnormalities compared to controls. 4

Bed Rest: No Evidence-Based Recommendation

The available guidelines do not support bed rest as an evidence-based intervention for threatened abortion or miscarriage prevention. The evidence focuses on progestogen therapy rather than bed rest, which was used only as a control/standard care comparator in studies. 1, 2

Key Clinical Pitfalls

  • Do not rely on bed rest alone: Studies comparing dydrogesterone to "conservative therapy" (which included bed rest) showed significantly better outcomes with active hormonal treatment. 1

  • Timing matters: Dydrogesterone is most effective when a viable fetus has been confirmed by ultrasound at the time of threatened abortion. 5

  • Exclude recurrent miscarriage history in acute threatened abortion studies: Women with history of recurrent miscarriage require different treatment protocols (continuous therapy until 12 weeks vs one-week course). 1, 4

Important Context: Progestogens NOT Indicated for Preterm Birth Prevention

While dydrogesterone is effective for threatened abortion, different progestogens are recommended for preterm birth prevention: 17-alpha-hydroxyprogesterone caproate 250 mg IM weekly (16-20 weeks until 36 weeks) for singleton gestations with prior preterm birth, or vaginal progesterone for short cervical length. 6

  • Progestogens have no proven benefit for multiple gestations, active preterm labor, or preterm premature rupture of membranes. 6

References

Research

Dydrogesterone in threatened abortion: pregnancy outcome.

The Journal of steroid biochemistry and molecular biology, 2005

Research

A systematic review of dydrogesterone for the treatment of threatened miscarriage.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2012

Research

Dydrogesterone in the reduction of recurrent spontaneous abortion.

The Journal of steroid biochemistry and molecular biology, 2005

Research

Progestogens for treatment and prevention of pregnancy disorders.

Hormone molecular biology and clinical investigation, 2010

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.